Bellicum Pharmaceuticals Stock News

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity induce

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -

Upgrades According to Compass Point, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Buy. Comerica earned $1.66 in the fourth quarter, compared to $1.49 in the year-ago quarte

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick F

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News .

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.

In todays recent session, 0.77 million Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) shares changed hands as the companys beta touched 1.52. With the companys per share price at $1.53 changed hands at -$0.16 or -9.47% during last session, the market valuation stood at $14.91M. BLCMs last price was a discount, traded about -432.68% off its 52-week high Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM): This Is The Year For Success Over The Next Few Months Read More »

(RTTNews) - Bellicum Pharmaceuticals, Inc. (BLCM) reported positive interim data from ongoing phase 1/2 GoCAR-T clinical trials, including a confirmed partial response in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. Charity Scripture, Chief Development Officer of Bellicum, said: "The early clinical activity we

Squarepoint Ops LLC cut its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 41.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,327 shares of the biopharmaceutical companys stock after selling 11,588 shares during the quarter. Squarepoint Ops LLC []

Vanguard Group Inc. raised its holdings in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 111.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 424,311 shares of the biopharmaceutical companys stock after acquiring an additional 223,524 shares during the quarter. Vanguard Group Inc. owned approximately 5.05% of []

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) saw a significant decrease in short interest during the month of October. As of October 29th, there was short interest totalling 626,200 shares, a decrease of 19.5% from the October 14th total of 777,700 shares. Currently, 7.5% of the company’s shares are sold short. Based on an average daily trading volume, […]

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fai

The stock price of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) increased over 12% pre-market. This is why it happened.

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas M